Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

American Marconi Wireless News - Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference taking place June 3-5, 2025, in New York, NY. The Company will also participate in one-on-one meetings.

Text size:

Jefferies Global Healthcare Conference - June 3-5, 2025

Format: Company Presentation
Day/Time: Wednesday, June 4 at 1:25 P.M. ET
Webcast: https://wsw.com/webcast/jeff319/ptgx/1883080

If you are interested in meeting with the Protagonist team during the conference, please reach out to your Jefferies representative.

A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.

About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides, icotrokinra and rusfertide, derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.

Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]

Media Contact
Virginia Amann, Founder/CEO
+1 833 500 0061 ext 1
ENTENTE Network of Companies
[email protected]

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

D.Kaufman--AMWN

RBGPF	6.25%	67.2	$
RYCEF	2.06%	11.15	$
NGG	0.57%	73.84	$
RELX	0.69%	55.37	$
SCS	-1.13%	10.135	$
RIO	0.3%	62.43	$
BCC	-1.38%	88.695	$
GSK	0.83%	38.72	$
VOD	0.95%	10.49	$
CMSC	-0.59%	22.13	$
BCE	-0.79%	21.49	$
BTI	0.6%	44.71	$
BP	0.12%	29.235	$
AZN	0.65%	70.38	$
JRI	0.08%	12.83	$
CMSD	-1.09%	21.93	$

American Marconi Wireless News - Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

Featured

Vietnam jails 23 people over rare earths exploitation

Macron party backs banning hijab in public spaces for under 15s

Cyberattack costs UK retailer Marks & Spencer £300 mn

Flood victims stranded on roofs as downpours lash eastern Australia